0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
BioMarin Pharmaceutical (NasdaqGS:BMRN) announced a major debt financing package to support its pending acquisition of Amicus Therapeutics. The company plans to offer US$850 million in senior unsecured notes alongside new term loan facilities. Proceeds are intended to fund the acquisition and related costs, with the transaction expected to reshape BioMarin's capital structure and rare disease portfolio. BioMarin focuses on therapies for rare genetic conditions, a corner of biopharma where approvals and commercial products can be highly concentrated in a few key assets. By targeting Amicus Therapeutics, BioMarin is looking to combine its existing rare disease franchise with Amicus's approved treatments, creating a broader set of therapies for similar patient populations. For investors, the move highlights how rare disease companies often use acquisitions to add products rather than relying only on internal research. The financing signals a clear intent to close the Amicus deal [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
BioMarin Pharmaceutical (NasdaqGS:BMRN) announced a major debt financing package to support its pending acquisition of Amicus Therapeutics. The company plans to offer US$850 million in senior unsecured notes alongside new term loan facilities. Proceeds are intended to fund the acquisition and related costs, with the transaction expected to reshape BioMarin's capital structure and rare disease portfolio. BioMarin focuses on therapies for rare genetic conditions, a corner of biopharma where approvals and commercial products can be highly concentrated in a few key assets. By targeting Amicus Therapeutics, BioMarin is looking to combine its existing rare disease franchise with Amicus's approved treatments, creating a broader set of therapies for similar patient populations. For investors, the move highlights how rare disease companies often use acquisitions to add products rather than relying only on internal research. The financing signals a clear intent to close the Amicus deal [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS